Physician profile
Gary S Mcdaniel
NPI 1407198286
$8,899.59
in general payments reported to CMS, 2019-2025
33 companies · $936 in 2025
The $936 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $738 · 2021: $1,459 · 2022: $2,445 · 2023: $1,142 · 2024: $1,440 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,517.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,408.38 | 2019-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $700.68 | 2019-2025 | General - Pain Management |
| Collegium Pharmaceutical, INC. | $305.55 | 2019-2025 | Belbuca |
| Valinor Pharma, LLC | $214.68 | 2023-2025 | Movantik |
| Lundbeck LLC | $194.30 | 2022-2024 | Vyepti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.96 | 2020-2025 | Relistor |
| Si-Bone, INC. | $175.28 | 2021-2022 | |
| Medtronic USA, INC. | $166.92 | 2019-2020 | |
| Nevro Corp. | $157.63 | 2019-2024 | Senza |
| Virtus Pharmaceuticals LLC | $147.47 | 2021-2025 | Levorphanol Tartrate |
| Abbvie INC. | $142.77 | 2022-2025 | |
| Scilex Pharmaceuticals INC. | $116.21 | 2023-2025 | Ztlido |
| Biotronik Nro, INC. | $115.33 | 2025 | Prospera |
| Azurity Pharmaceuticals, INC. | $110.67 | 2023-2024 | Horizant, Horizant |
| Medtronic, INC. | $98.83 | 2021-2025 | Intellis Adaptivestim |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $82.21 | 2025 | Evoke |
| Avanos Medical | $69.01 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $66.95 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.03 | 2022 | |
| Horizon Therapeutics Plc | $53.60 | 2019-2022 | |
| Stryker Corporation | $44.43 | 2022 | |
| Ibsa Pharma INC. | $38.12 | 2024-2025 | Flector, Licart, Tirosint |
| Pfizer INC. | $37.31 | 2023 | |
| Spr Therapeutics, INC | $29.37 | 2024 | Sprint Pns System |
| Relievant Medsystems, INC. | $29.27 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $23.88 | 2023 | Ajovy |
| Spinal Simplicity, LLC | $23.75 | 2023 | Ha Minuteman G3-R |
| Globus Medical, INC. | $20.98 | 2025 | Senza |
| Biohaven Pharmaceuticals, INC. | $18.03 | 2021 | |
| Bioventus LLC | $17.81 | 2023 | Durolane |
| Vertex Pharmaceuticals Incorporated | $17.07 | 2024 | |
| Vertos Medical, INC. | $11.64 | 2024 | Mild Device Kit |
| Nalu Medical, INC. | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.